liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Effects of High-Dose Atorvastatin in Patients =65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study)
Linköping University, Department of Medicine and Health Sciences, Internal Medicine . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Medicine, Department of Endocrinology and Gastroenterology UHL.
VA Medical Center, University of Colorado Health Sciences, Denver, CO, United States.
Pfizer, Inc., New York, NY, United States.
Pfizer, Inc., New York, NY, United States.
Show others and affiliations
2007 (English)In: American Journal of Cardiology, ISSN 0002-9149, Vol. 99, no 5, 632-635 p.Article in journal (Refereed) Published
Abstract [en]

After acute coronary syndromes (ACSs), older patients are particularly susceptible to early complications, including death and recurrent ACS. Lipid management guidelines do not differentiate elderly from younger patients, and lack of evidence for statin benefits in older patients has led to underutilization of statins in the elderly. The MIRACL study randomized 3,086 patients to 16 weeks of 80 mg/day of atorvastatin or placebo 24 to 96 hours after ACS and demonstrated significant decreases in the combined primary end point (nonfatal acute myocardial infarction, resuscitated cardiac arrest, recurrent symptomatic myocardial ischemia). This post hoc analysis compared benefits of 80 mg of atorvastatin in older (=65 years) versus younger (<65 years) patients. Event rates were approximately two- to threefold higher in older than in younger patients. Treatment-by-age heterogeneity testing indicated no difference in treatment effect by age for any of the primary or secondary end points, and relative risk decreases in the primary end point with atorvastatin versus placebo were similar in younger and older patients (22% vs 14%, respectively). The safety profile of atorvastatin was similar between the 2 age groups. In conclusion, these results and a greater immediate cardiovascular risk in older patients argue for early, intensive atorvastatin therapy as routine practice after ACS. © 2007 Elsevier Inc. All rights reserved.

Place, publisher, year, edition, pages
2007. Vol. 99, no 5, 632-635 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-49969DOI: 10.1016/j.amjcard.2006.09.111OAI: diva2:270865
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2010-01-27

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Olsson, Andes G.
By organisation
Internal Medicine Faculty of Health SciencesDepartment of Endocrinology and Gastroenterology UHL
In the same journal
American Journal of Cardiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 7 hits
ReferencesLink to record
Permanent link

Direct link